Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | HK1 | P19367 | 1/20 | 0.36 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6840916 | 0.91 | FAP (0.42) | FAPCYP3A4CYP1A2SLC29A1CYP2D6 | |
| SCHEMBL6846259 | 0.87 | CYP3A4 (0.52) | CYP3A4CYP1A2SLC29A1HK1HKDC1 | |
| SCHEMBL6846402 | 0.86 | FAP (0.41) | FAPCYP3A4CYP1A2SLC29A1HK1 | |
| SCHEMBL6846399 | 0.86 | CYP3A4 (0.40) | CYP3A4CYP1A2SLC29A1HK1HKDC1 | |
| SCHEMBL13268950 | 0.85 | FAP (0.39) | FAPCYP3A4CYP1A2SLC29A1CYP2D6 | |
| SCHEMBL6846396 | 0.85 | SLC22A6 (0.39) | FAPCYP3A4CYP1A2SLC29A1HK1 | |
| SCHEMBL7124772 | 0.83 | CYP1A2 (0.39) | CYP3A4CYP1A2SLC29A1HK1HKDC1 | |
| SCHEMBL7117963 | 0.83 | CYP1A2 (0.39) | CYP3A4CYP1A2SLC29A1HK1HKDC1 | |
| SCHEMBL7118739 | 0.78 | CYP3A4 (0.50) | CYP3A4CYP1A2SLC29A1HK1HKDC1 | |
| SCHEMBL13268948 | 0.78 | CYP3A4 (0.37) | FAPCYP3A4CYP1A2SLC29A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6767900-B2 | VIRICIDES AGAINST HERPES, HUMAN IMMUNODEFICIENCY, HEPATITIS, CYTOMEGALO AND VARICELLA- ZOSTER VIRUSES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-07-27 | — | — | US | claimed |
| US-20030153534-A1 | Phosphonate nucleotide compound | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-14 | — | — | US | claimed |
| US-6767900-B2 | VIRICIDES AGAINST HERPES, HUMAN IMMUNODEFICIENCY, HEPATITIS, CYTOMEGALO AND VARICELLA- ZOSTER VIRUSES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-07-27 | — | — | US | disclosed |
| US-20030153534-A1 | Phosphonate nucleotide compound | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153534-A1 | Phosphonate nucleotide compound | TYMP, PNP, MTAP | FAP 633/4885CYP3A4 958/4885CYP1A2 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.